The field of theranostics is rapidly advancing, driven by the goals of enhancing patient care.
Recent breakthroughs in artificial intelligence (AI) and its innovative theranostic applications …

The strategies of future medicine are aimed to modernize and integrate quality approaches
including early molecular-genetic profiling, identification of new therapeutic targets and …

Our objective was to determine the diagnostic value of prostate-specific membrane antigen
(PSMA) PET/CT in staging men with newly diagnosed unfavorable intermediate-risk prostate …

Approximately 5% of patients with D'Amico intermediate-to high-risk, hormone-sensitive
prostate cancer (PCa) have a tumour that lacks prostate-specific membrane antigen (PSMA) …

Purpose Primary objective was to compare the per-patient detection rates (DR) of [18F]
DCFPyL versus [18F] fluoromethylcholine positron emission tomography/computed …

Background and objectives The association between prostate-specific antigen (PSA) level
and probability of metastatic disease on prostate-specific membrane antigen (PSMA) …

Prostate specific membrane antigen (PSMA) directed PET imaging has rapidly transformed
prostate cancer workup over the past decade and paved the way for a theranostic approach …

Background/objectives This study reassesses the diagnostic value of PSMA PET/CT in
unfavorable intermediate-risk prostate cancer (PCa) and validates the Prostate Cancer …

Purpose Accurate diagnosis and staging of prostate cancer are crucial to improving patient
care. Prostate-specific membrane antigen (PSMA)-targeted positron emission tomography …

The treatment landscape of metastatic castrate-resistant prostate cancer (mCRPC) has been
dramatically transformed over the past two decades by several leapfrog advances including …